Data Characteristics
Data for Antibody-Drug Conjugate (ADC) clinical trial pre-screening originates from global clinical trial registries (e.g., ClinicalTrials.gov, EU Clinical Trials Register), biomedical literature databases (e.g., PubMed, Scopus), patent databases, drug development reports, and internal pharmaceutical company research data. This data updates frequently; clinical trial registration information may update weekly, while literature and patent data are continuously published. Document structures vary, including structured trial record tables, unstructured research protocol documents, Case Report Forms (CRFs), and various research reports. Field and unit specificities involve the strict definition and use of biomedical terms and units, such as target expression, linker type, toxic payload, drug-antibody ratio (DAR), PK/PD parameters, adverse event (AE) grading, and solid tumor or hematological malignancy staging.
Constraints on Vector Models and Indexing
The high update frequency of ADC clinical trial data requires vector indexes to support efficient incremental updates, ensuring the timeliness of pre-screening results. Diverse document structures, especially a large volume of unstructured text, challenge text preprocessing and the generalization capability of vectorization models. Models must accurately capture complex semantics within the biomedical domain. ADC-specific biomolecule fields like targets and linkers, along with numerical fields such as PK/PD parameters, require vector models to integrate structured and unstructured information and deeply understand specialized terminology. Additionally, medical-specific units and grading systems, such as adverse event grading, demand that vector indexes differentiate clinical significance across various grades during similarity calculations. This prevents simple text matching errors and ensures the clinical relevance of retrieval results.
Configuration Guidelines
| Configuration Item | Recommended Approach | Rationale |
|---|---|---|
chunk_size | 512–768 characters | Balances context completeness with vectorization efficiency, preventing critical information dilution in long texts. |
overlap_size | 64–128 characters | Ensures contextual continuity between segments, reducing the risk of critical information being truncated. |
embedding_model | text-embedding-3-large or bge-large-zh-v1.5 | Selects high-dimensional, high-performance models to enhance semantic capture for specialized biomedical vocabulary and complex semantics. |
top_k | 10–20 items | Initially retrieves a sufficient number of potentially relevant results, providing a rich candidate set for subsequent reranking. |
rerank_model | bge-reranker-large | Refines the ranking of initial retrieval results, improving accuracy and relevance. |
similarity_threshold | Calibrated by empirical measurement | Adjusts based on actual cases to balance recall and precision, adhering to the strict requirements of clinical trial pre-screening. |
Common Pitfalls
- Issue: Pre-screening results contain many irrelevant or low-relevance clinical trials, sometimes including non-ADC drugs. Reason: The vector model lacks sufficient understanding of the deep semantics of ADC drugs, such as their unique molecular structures and mechanisms of action, leading to poor discriminative power in vector representations.
- Issue: After a knowledge base update, newly imported clinical trial data is not retrieved promptly. Reason: The indexing mechanism is not configured for incremental updates, or incremental update efficiency is low, preventing new data from being effectively vectorized and included in the index.
- Issue: When querying specific targets or toxic payload types, retrieval results are poorly ordered, with important trial information ranked lower. Reason: Similarity calculation relies solely on vector distance and does not incorporate key field weighting or the reranking model's ability to recognize specialized biomedical terminology.
Validation Steps
- Perform a series of complex queries including keywords such as ADC targets, linkers, toxic payloads, and indications. Check if the
top_kretrieved items include highly relevant clinical trials and assess the reasonableness of their ranking. - Import a batch of the latest ADC clinical trial data. After the index update completes, immediately execute queries targeting this new data to confirm its effective retrieval.
- Randomly select real-world clinical trial pre-screening cases. Compare manual screening results with system retrieval results. Calculate recall and precision, and set an acceptable qualification threshold based on business requirements.
The values provided are common starting points and should be measured against the reader's own samples.
Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.